1. Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974–1982 (2015).
2. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
3. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
4. Haslam, A. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw. Open. 2, e192535 (2019).
5. Krieg, A. M. Therapeutic potential of toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5, 471–484 (2006).
6. Klinman, D. M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4, 249–258 (2004).
7. Boukhaled, G. M., Harding, S. & Brooks, D. G. Opposing roles of type I interferons in cancer immunity. Annu. Rev. Pathol. 16, 167–198 (2021).
8. Karapetyan, L., Luke, J. J. & Davar, D. Toll-like receptor 9 agonists in cancer. Oncol. Targets Ther. 13, 10039–10060 (2020).
9. Kobiyama, K. et al. Nonagonistic dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist. Proc. Natl Acad. Sci. USA 111, 3086–3091 (2014).
10. Hanagata, N. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int. J. Nanomedicine. 7, 2181–2195 (2012).
11. Honda, K. et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434, 1035– 1040 (2005).
12. Sabree, S. A. et al. Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist. J. Immunother. Cancer. 9, e002484 (2021).
13. Ribas, A. et al. Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with meta- static melanoma. Cancer Discov. 11, 2998–3007 (2021).
14. McHutchison, J. G. et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 46, 1341–1349 (2007).
15. Bode, C., Zhao, G., Steinhagen, F., Kinjo, T. & Klinman, D. M. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines. 10, 499–511 (2011).
16. Vollmer, J. et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34, 251–262 (2004).
17. Yokokawa, H. et al. Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model. Gut 67, 372–379 (2018).
18. Yamamoto, T. et al. A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection. Int. Immunol. 31, 81–90 (2019).
19. Masuta, Y. et al. An antigen-free, plasmacytoid dendritic cell-targeting immunotherapy to bolster memory CD8+ T cells in nonhu- man primates. J. Immunol. 200, 2067–2075 (2018).
20. Ito, H. et al. Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand. J. Viral Hepat. 24, 155–162 (2017).
21. Kitahata, Y. et al. Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells. Oncotarget 7, 48860–48869 (2016).
22. Hammerich, L., Binder, A. & Brody, J. D. In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. Mol. Oncol. 9, 1966–1981 (2015).
23. Sheen, M. R. & Fiering, S. In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 11, e1524 (2019).
24. Zhang, Z. et al. Neoantigen: A new breakthrough in tumor immunotherapy. Front. Immunol. 12, 672356 (2021).
25. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
26. Tempero, M. A. et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 19, 439–457 (2021).
27. Benson, A. B. et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 19, 329–359 (2021).
28. Ascunce, G. et al. EUS visualization and direct celiac ganglia neurolysis predicts better pain relief in patients with pancreatic malignancy (with video). Gastrointest. Endosc. 73, 267–274 (2011).
29. Matsumoto, K. et al. Efficacy and safety of scheduled early endoscopic ultrasonography-guided ethanol reinjection for patients with pancreatic neuroendocrine tumors: Prospective pilot study. Dig. Endosc. 32, 425–430 (2020).
30. Vonderheide, R. H. CD40 agonist antibodies in cancer immunotherapy. Annu. Rev. Med. 71, 47–58 (2020).
31. Meric-Bernstam, F., Larkin, J., Tabernero, J. & Bonini, C. Enhancing anti-tumour efficacy with immunotherapy combinations.Lancet 397, 1010–1022 (2021).
32. Haymaker, C. et al. 1083MO final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma. Ann. Oncol. 31(suppl 4), S736 (2020).
33. Babiker, H. B. et al. A phase 2 multicenter study to evaluate the efficacy of tilsotolimod in combination with nivolumab and ipili- mumab for treatment of microsatellite-stable colorectal cancer (ILLUMINATE-206). Cancer Res. 80(16), abstract CT265 (2020).
34. Geboers, B. et al. Irreversible electroporation and nivolumab combined with intratumoral administration of a toll-like receptor ligand, as a means of in vivo vaccination for metastatic pancreatic ductal adenocarcinoma (PANFIRE-III). A phase-I study protocol. Cancers (Basel) 13, 3902 (2021).
35. Carbone, C. et al. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer. J. Immunother. Cancer. 9, e002876 (2021).
36. Ribas, A. et al. SD-101 in combination with pembrolizumab in advanced melanoma: Results of a phase Ib, multicenter study.Cancer Discov. 8, 1250–1257 (2018).
37. Kapp, K. et al. Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors. Oncoimmunology. 8, e1659096 (2019).
38. Milhem, M. et al. O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab. J. Immunother. Cancer. 8(suppl 1), A1–A12 (2020).
39. Negrao, M. et al. FP03.05 TLR9 agonist CMP-001 plus Atezolizumab +/- radiation therapy in patients with PD-1 blockade resistant advanced NSCLC. J. Thorac. Oncol. 16(suppl 3), S196 (2021).
40. Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).
41. June, C. H., Warshauer, J. T. & Bluestone, J. A. Is autoimmunity the Achilles’ heel of cancer immunotherapy?. Nat. Med. 23, 540–547 (2017).
42. Lemke-Miltner, C. D. et al. Antibody opsonization of a TLR9 agonist-containing virus-like particle enhances in situ immunization. J. Immunol. 204, 1386–1394 (2020).
43. Wang, S. et al. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc. Natl Acad. Sci. USA 113, E7240–E7249 (2016).
44. Brody, J. In situ vaccination as a therapy for low-grade lymphoma. Clin. Adv. Hematol. Oncol. 13, 26–28 (2015).
45. Kaufman, H. L. et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 17, 718–730 (2010).
46. Senzer, N. N. et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27, 5763–5771 (2009).
47. Younes, A. I. et al. Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity. Transl. Oncol. 14, 100983 (2021).
48. Cai, Z. et al. Photodynamic therapy combined with antihypoxic signaling and CpG adjuvant as an in situ tumor vaccine based on metal-organic framework nanoparticles to boost cancer immunotherapy. Adv. Healthc. Mater. 9, e1900996 (2020).
49. Silvestrini, M. T. et al. Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols.JCI Insight. 2, e90521 (2017).
50. Narayanan, J. S. S. et al. Irreversible electroporation combined with checkpoint blockade and TLR7 stimulation induces antitumor immunity in a murine pancreatic cancer model. Cancer Immunol. Res. 7, 1714–1726 (2019).
51. Veenstra, J. J. et al. Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity. Cancer Res. 74, 5409–5420 (2014).
52. Moletta, L. et al. Surgery for recurrent pancreatic cancer: Is it effective?. Cancers (Basel) 11, 991 (2019).
53. Fuccio, L. et al. New and recurrent colorectal cancers after resection: A systematic review and meta-analysis of endoscopic surveil- lance studies. Gastroenterology 156, 1309-1323.e3 (2019).
54. Bakos, O., Lawson, C., Rouleau, S. & Tai, L. H. Combining surgery and immunotherapy: Turning an immunosuppressive effect into a therapeutic opportunity. J. Immunother. Cancer. 6, 86 (2018).
55. Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 25, 454–461 (2019).
56. Nishikawa, Y. et al. Hes1 plays an essential role in Kras-driven pancreatic tumorigenesis. Oncogene 38, 4283–4296 (2019).
57. Tsuda, M. et al. The BRG1/SOX9 axis is critical for acinar cell-derived pancreatic tumorigenesis. J. Clin. Invest. 128, 3475–3489 (2018).
論文の公開元へ
